Inventor · disambiguated record
Peihong Dai
Also filed as: DAI PEIHONG
13 granted patents·2 pending applications·60 citations·filing 2016–2025
90Inventor score
Files withMEMORIAL SLOAN KETTERING CANCER CENTER15
Top patents by PatentIndex Score
15 records- 0196US10736962B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Aug 11, 2020·15 cites·22 claims
- 0295US12036279B2Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Jul 16, 2024·2 cites·8 claims
- 0395US11986503B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted May 21, 2024·2 cites·14 claims
- 0494US11285209B2Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Mar 29, 2022·3 cites·10 claims
- 0594US11253560B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Feb 22, 2022·3 cites·19 claims
- 0694US10639366B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted May 5, 2020·10 cites·16 claims
- 0794US10548930B2Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 4, 2020·15 cites·18 claims
- 0893US11541087B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Jan 3, 2023·2 cites·12 claims
- 0993US10512662B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Dec 24, 2019·6 cites·20 claims
- 1087US10765711B2Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Sep 8, 2020·2 cites·19 claims
- 1184US2025177518A1Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2024·Application pending·0 cites
- 1279US12397029B2Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Granted Aug 26, 2025·0 cites·13 claims
- 1370US12252702B2Recombinant poxviruses for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Mar 18, 2025·0 cites·24 claims
- 1463US11426460B2Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumorsMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Aug 30, 2022·0 cites·20 claims
- 1562US2025179524A1Recombinant poxviruses for cancer immunotherapyMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peihong Dai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →